Zhejiang Wolwo Bio-Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Zhejiang Wolwo Bio-Pharmaceutical has a total shareholder equity of CN¥2.5B and total debt of CN¥37.2M, which brings its debt-to-equity ratio to 1.5%. Its total assets and total liabilities are CN¥2.7B and CN¥231.7M respectively. Zhejiang Wolwo Bio-Pharmaceutical's EBIT is CN¥304.5M making its interest coverage ratio -8.3. It has cash and short-term investments of CN¥1.3B.
Key information
1.5%
Debt to equity ratio
CN¥37.22m
Debt
| Interest coverage ratio | -8.3x |
| Cash | CN¥1.25b |
| Equity | CN¥2.47b |
| Total liabilities | CN¥231.71m |
| Total assets | CN¥2.70b |
Recent financial health updates
These 4 Measures Indicate That Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Is Using Debt Reasonably Well
Sep 26
Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
Mar 22Recent updates
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) P/E Is Still On The Mark Following 39% Share Price Bounce
Sep 30These 4 Measures Indicate That Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Is Using Debt Reasonably Well
Sep 26Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185
Jun 30Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking
May 27Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)
May 07Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
Mar 22Financial Position Analysis
Short Term Liabilities: 300357's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥163.4M).
Long Term Liabilities: 300357's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥68.3M).
Debt to Equity History and Analysis
Debt Level: 300357 has more cash than its total debt.
Reducing Debt: 300357's debt to equity ratio has increased from 0% to 1.5% over the past 5 years.
Debt Coverage: 300357's debt is well covered by operating cash flow (781.7%).
Interest Coverage: 300357 earns more interest than it pays, so coverage of interest payments is not a concern.